Published in Blood Weekly, November 18th, 2004
The two phase 1 clinical studies were conducted at Duke University Medical Center under lead investigator John S. Sundy, MD. Each study was designed to evaluate the safety, tolerability, and pharmacokinetics of a range of single doses of Puricase in subjects with hyperuricemia associated with severe refractory gout.
At the time of enrollment in the study, the overall quality of life...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.